Ornithine Decarboxylase mRNA Expression in Curatively Resected Non-Small-Cell Lung Cancer

被引:9
|
作者
Grimminger, Peter P. [1 ]
Schneider, Paul M. [2 ]
Metzger, Ralf
Vallboehmer, Daniel
Danenberg, Kathleen D. [3 ]
Danenberg, Peter V. [4 ]
Hoelscher, Arnulf H.
Brabender, Jan
机构
[1] Univ Cologne, Dept Gen Visceral & Canc Surg, Univ Clin Cologne, D-50937 Cologne, Germany
[2] Univ Clin Zurich, Dept Visceral & Transplant Surg, Zurich, Switzerland
[3] Response Genet Inc, Los Angeles, CA USA
[4] Univ So Calif, Fac Biochem & Mol Biol, Los Angeles, CA USA
关键词
beta-actin; Biomarkers; DFMO; Nontumorous lung tissue; Real-time RT-PCR; DL-ALPHA-DIFLUOROMETHYLORNITHINE; CHI-SQUARE STATISTICS; POLYAMINE METABOLISM; PANCREATIC-CANCER; ESOPHAGEAL CANCER; BREAST-CANCER; GROWTH; ADENOCARCINOMA; TRANSFORMATION; CARCINOMA;
D O I
10.3816/CLC.2010.n.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The effect of ornithine decarboxylase (ODC) on the pathogenesis of non-small-cell lung cancer (NSCLC) remains poorly investigated. Hence, the aim of this study was to explore the potential role of ODC mRNA expression as a prognostic biomarker in patients with curatively resected NSCLC. Patients and Methods: A total of 91 tumor and matching nontumorous lung tissue samples from patients with NSCLC were analyzed using a quantitative realtime reverse-transcriptase polymerase chain reaction method. The relative ODC mRNA expression was measured in tumorous and nontumorous lung tissue using beta-actin as a reference gene. Squamous cell carcinoma was found in 43 patients (47%), adenocarcinoma in 33 (36%), and large-cell carcinoma in 15 of the patients (17%). All patients' disease was R0 resected. Results: Ornithine decarboxylase was detected in all 91 tumor and nontumorous lung tissue samples. The median tumorous expression of 9.11 (range, 0.92-155.35) was significantly elevated compared with the median ODC expression of 7.89 (range, 0.0-45.8) in nontumorous lung tissue. Ornithine decarboxylase expression levels were not associated with any clinicopathologic parameters. Using an ODC/beta-actin ratio of 10 as a cutoff, tumorous ODC (tODC) expression is a significant prognostic factor in NSCLC. The ODC ratio between tumorous and nontumorous expression was even more prognostic. Moreover, Cox proportional hazards model analysis showed ODC expression to be an independent prognostic factor. Conclusion: In this study, ODC is shown to have a prognostic potential in NSCLC. Low levels of tODC expression are associated with a more aggressive tumor biology. Also, an increase of ODC mRNA expression during carcinogenesis seems to have a favorable prognostic effect. Measuring the ODC expression in patients with NSCLC could aid in further chemotherapy decisions. Our results suggest that further investigation of ODC mRNA expression in NSCLC may be warranted.
引用
收藏
页码:114 / 119
页数:6
相关论文
共 50 条
  • [1] ODC mRNA expression in curatively resected non-small cell lung cancer (NSCLC)
    Grimminger, Peter P.
    Danenberg, Peter V.
    Daniel, Vallboehmer
    Schneider, Paul M.
    Hoelscher, Arnulf H.
    Brabender, Jan
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (06) : S239 - S239
  • [2] The prognostic role of Bcl-2 mRNA expression in curatively resected non-small cell lung cancer (NSCLC)
    Grimminger, Peter P.
    Schneider, Paul M.
    Metzger, Ralf
    Vallboehmer, Daniel
    Danenberg, Kathleen D.
    Danenberg, Peter V.
    Hoelscher, Arnulf H.
    Brabender, Jan
    LUNG CANCER, 2010, 70 (01) : 82 - 87
  • [3] Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer
    Tanabe, H
    Yagihashi, A
    Tsuji, N
    Shijubo, Y
    Abe, S
    Watanabe, N
    LUNG CANCER, 2004, 46 (03) : 299 - 304
  • [4] Treatment of resected non-small-cell lung cancer
    Bria, E
    Giannarelli, D
    Terzoli, E
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (14): : 1523 - 1523
  • [5] Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer
    Harada, Hiroaki
    Miyamoto, Kazuaki
    Yamashita, Yoshinori
    Taniyama, Kiyomi
    Mihara, Kazuko
    Nishimura, Mitsuki
    Okada, Morihito
    CANCER MEDICINE, 2015, 4 (10): : 1536 - 1546
  • [6] Elevated serum bilirubin levels are associated with improved survival in patients with curatively resected non-small-cell lung cancer
    Li, Ning
    Xu, Miao
    Cai, Mu-Yan
    Zhou, Feng
    Li, Chao-Feng
    Wang, Bao-Xiao
    Ou, Wei
    Wang, Si-Yu
    CANCER EPIDEMIOLOGY, 2015, 39 (05) : 763 - 768
  • [7] Adjuvant therapy of resected non-small-cell lung cancer
    Keller, SM
    CURRENT OPINION IN ONCOLOGY, 2000, 12 (02) : 149 - 155
  • [8] Adjuvant chemotherapy for resected non-small-cell lung cancer
    Solomon, Benjamin
    Mitchell, John D.
    Bunn, Paul A., Jr.
    ONCOLOGY-NEW YORK, 2005, 19 (13): : 1685 - 1697
  • [9] Expression Profiles and Clinicopathologic Features in Early Resected Non-small-cell Lung Cancer
    Rosell, Rafael
    EBIOMEDICINE, 2014, 1 (2-3): : 103 - 104
  • [10] CLINICAL SIGNIFICANCE OF KI67 EXPRESSION IN CURATIVELY RESECTED NON-SMALL CELL LUNG CANCER
    Ahn, Hee Kyung
    Jung, Minkyu
    Kang, Shin Myung
    Park, Inkeun
    Kim, Young Saing
    Lee, Jae-Ik
    Cho, Eun Kyung
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1216 - S1217